Karyopharm Therapeutics Inc. income statement

In fiscal 2025, Karyopharm Therapeutics Inc. reported revenue of $146m, up 0.6% on the year before, operating income of −$90.7m (a -62.1% margin) and net income of −$196m, or −$17.93 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Karyopharm Therapeutics Inc.: income statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	1	0	0	0	0	2	30	41	108	210	157	146	145	146	147
Research and development	9	14	28	60	98	87	107	161	122	151	161	149	139	143	126	121
Selling, general and administrative	—	—	—	—	—	—	25	49	105	126	144	145	132	115	105	102
General and administrative	2	2	6	16	22	24	—	—	—	—	—	—	—	—	—	—
Operating income	−10	−16	−34	−76	−119	−111	−131	−180	−189	−172	−98	−142	−130	−119	−91	−82
Interest expense	—	—	—	0	—	—	—	2	16	27	26	25	24	37	46	49
Income before tax	—	—	—	−76	−118	−109	−129	−178	−200	−196	−124	−165	−143	−76	−196	−225
Income tax	—	−16	−34	−76	−118	0	0	0	0	0	0	0	0	0	0	−0
Net income	−10	−16	−34	−76	−118	−110	−129	−178	−200	−196	−124	−165	−143	−76	−196	−225
Diluted EPS	−$923.26	−$804.59	−$502.53	−$72.82	−$99.49	−$87.50	−$84.21	−$1411.41	−$1447.37	−$1222.62	−$49.44	−$907.98	−$18.79	−$14.00	−$17.93	—
Diluted shares (average)	—	—	—	—	—	—	—	—	—	—	—	182m	—	—	11m	—
EBITDA	−10	−16	−34	−76	−118	−110	−130	−179	−188	−171	−97	−142	−129	−119	−90	−82

US$ millions unless shown otherwise. Fiscal quarters.

Karyopharm Therapeutics Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	39	31	30	38	44	34	35	33
Research and development	36	33	35	33	31	28	34	29
Selling, general and administrative	28	27	27	28	27	23	27	26
Operating income	−26	−31	−33	−24	−15	−18	−27	−23
Interest expense	11	11	11	11	11	13	13	13
Income before tax	−32	−31	−23	−37	−33	−102	−22	−67
Income tax	0	−0	0	0	0	−0	0	0
Net income	−32	−31	−23	−37	−33	−102	−22	−67
Diluted EPS	−$115.37	−$3.60	−$2.77	−$4.32	−$114.47	−$7.00	−$1.24	−$2.32
EBITDA	−26	−31	−33	−24	−15	−18	−27	−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BEAM vs KPTI AGEN vs KPTI IBRX vs KPTI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Karyopharm Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Karyopharm Therapeutics Inc.